(Q40708483)

22 September 2017

Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer (English)

1 reference

22 September 2017

Bellmunt J

1

1 reference

22 September 2017

Cos J

2

1 reference

22 September 2017

Clèries R

3

1 reference

22 September 2017

Pérez M

4

1 reference

22 September 2017

Ribas A

5

1 reference

22 September 2017

Eres N

6

1 reference

22 September 2017

Murio JE

7

1 reference

22 September 2017

Margarit C

8

1 reference

22 September 2017

Baselga J

9

1 reference

22 September 2017

1 January 2002

1 reference

22 September 2017

1 reference

22 September 2017

20

1 reference

22 September 2017

673-685

1 reference

22 September 2017

5-6

1 reference

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

22 September 2017

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

Gemcitabine and paclitaxel combination therapy in transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

A phase I investigation of the sequential use of methotrexate and paclitaxel with and without G-CSF for the treatment of solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

Comparative study of sequential combinations of paclitaxel and methotrexate on a human bladder cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

Paclitaxel-based second-line therapy for patients with advanced chemotherapy-resistant bladder carcinoma (M1): a clinical Phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1081%2FCNV-120003536

21 January 2018

Identifiers

DOI

10.1081/CNV-120003536

1 reference

22 September 2017

1 reference